Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.31 |
| ▸ | PGR | P06401 | 3/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2722151 | 0.89 | AR (0.35) | ARNR3C1PGRNR3C2CYP1A2 | |
| SCHEMBL1806496 | 0.81 | CES2 (0.31) | — | |
| SCHEMBL6312251 | 0.80 | — | — | |
| SCHEMBL840344 | 0.80 | TSHR (0.35) | AR | |
| SCHEMBL16720954 | 0.78 | NR3C1 (0.35) | ARNR3C1PGRNR3C2 | |
| SCHEMBL29951411 | 0.77 | TRPV4 (0.34) | ARCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL385455 | 0.77 | TRPV4 (0.34) | ARCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL830482 | 0.77 | — | — | |
| SCHEMBL433113 | 0.75 | PLA2G7 (0.34) | ARNR3C1PGR | |
| SCHEMBL17099864 | 0.75 | LATS1 (0.33) | GABRA1GABRG2GABRB3GABRA2GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145935-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS DAG-LIPASE INHIBITORS | Universiteit Leiden (NL) | 2017-03-29 | — | — | EP | disclosed |
| WO-2016188972-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS DAG-LIPASE INHIBITORS | UNIVERSITEIT LEIDEN (NL) | 2016-12-01 | — | — | WO | disclosed |
| US-8273770-B2 | 5-pyridinone substituted indazoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2176251-B1 | 5-pyridinone substituted indazoles and pharmaceutical compositions thereof | ALBANY MOLECULAR RES INC (US) | 2012-02-08 | — | — | EP | disclosed |
| EP-2176251-A2 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | Albany Molecular Research, Inc. (US) | 2010-04-21 | — | — | EP | disclosed |
| US-20090082359-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | AMR TECHNOLOGY, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| WO-2009015037-A2 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082359-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | CYP3A5, PNPO, NDUFS3 | AR 3296/4885GABRA1 2095/4885GABRG2 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.